Keyphrases
Acral Lentiginous Melanoma
9%
Anthracyclines
12%
Brain Metastases
12%
Breast Cancer
100%
Breast Cancer Patients
17%
Breast Cancer Subtypes
15%
Cervical Cancer
11%
Clinical Features
9%
Clinical Trials
10%
Disease-free Survival
9%
Early Breast Cancer
13%
Epstein-Barr Virus
9%
Estrogen Receptor-positive
9%
Gastric Cancer
18%
Genotype
9%
Glioblastoma
32%
Gross Total Resection
8%
Helicobacter Pylori (H. pylori)
14%
Helicobacter Pylori Infection
9%
HER2-positive
9%
Hereditary Breast Cancer
9%
Hereditary Ovarian Cancer
9%
High-risk Human Papillomavirus (HR-HPV)
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Immuno-oncology
16%
Indigenous Americans
10%
Latin America (LATAM)
9%
Lima
8%
Malignancy
11%
Neoadjuvant Chemotherapy
23%
Neoplastic Disease
14%
Oncology Biomarkers
16%
Overall Survival
19%
P16 Staining
9%
Pathological Complete Response
10%
Pathologist
9%
Peru
37%
Peruvian
58%
Phase II Trial
12%
PIK3CA mutation
11%
Promoter Methylation
8%
Quantitative PCR
9%
Residual Disease
13%
Stromal Tumor-infiltrating Lymphocytes
14%
Taxanes
8%
Triple Negative
10%
Triple-negative Breast Cancer
33%
Tumor
20%
Tumor-infiltrating Immune Cells
12%
Tumor-infiltrating Lymphocytes
70%
Medicine and Dentistry
Abdominal Cancer
14%
Anthracycline
8%
Biological Marker
28%
Brain Metastasis
9%
Breast Cancer
88%
Breast Carcinoma
6%
Cancer
7%
Cancer Stem Cell
6%
Cancer Therapy
7%
Carcinoma in Situ
6%
Central Nervous System
6%
Cervical Cancer
9%
Chemotherapy
11%
Clinical Feature
7%
Clinical Stage
9%
Clinical Trial
15%
Disease
16%
Disease Free Survival
7%
Encephalitis
6%
Exon
6%
Fluorescein
6%
Glioblastoma
19%
Haematoxylin
6%
Helicobacter Pylori
10%
Immunity
7%
Immunocompetent Cell
7%
Immunoglobulin
16%
Malignant Neoplasm
27%
Metastatic Breast Cancer
6%
microRNA
9%
Microsurgery
6%
Minimal Residual Disease
14%
Neoadjuvant Chemotherapy
19%
Neoadjuvant Therapy
7%
Neoplasm
50%
Oncology
17%
Overall Survival
15%
P16
6%
Pathologist
6%
Polymerase Chain Reaction
6%
Prognostic Factor
7%
Programmed Death-Ligand 1
6%
Radiation Therapy
6%
Radical Hysterectomy
6%
Stromal Tumor
14%
Surgery
9%
Triple Negative Breast Cancer
33%
Tuberculosis Treatment
6%
Tumor Infiltrating Lymphocyte
61%
Wart Virus
9%